NEW YORK (GenomeWeb News) – A US federal district court has denied Myriad Genetics and other patent holders' request for a preliminary injunction against competitor Ambry Genetics to stop it from performing and selling tests that gauge BRCA genetic mutations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.